Tysabri (natalizumab)

Our study uncovered several immune-related drugs associated with increased breast cancer reporting in women with AIDs. This risk may be explained by several potential drug targets with causal roles, or by the shared genetic comorbidity between specific AIDs and breast cancer. These insights emphasize the need for tailored breast cancer surveillance and highlight potential molecular targets for intervention in vulnerable populations.

P=N/A, N=400, Active, not recruiting, Biogen | Trial completion date: Dec 2025 --> Mar 2026 | Trial primary completion date: Dec 2025 --> Mar 2026

This observational study showed a changing epidemiological context over 37 years. Although survival improved over time, it remained poor even in the last decade, with a one-year survival probability of 59.2%.

P4, N=800, Active, not recruiting, The Cleveland Clinic | Trial completion date: Sep 2030 --> Jul 2027

Our findings demonstrate that TDLs represent a radiological phenotype associated within a spectrum of neuroinflammatory disorders, with MS being the most frequent underlying diagnosis in our cohort. Although their often alarming radiological appearance, the long-term clinical outcomes are generally favorable. Although most commonly associated with MS, diagnostic clarification through MOG IgG and anti-aquaporin-4 IgG antibody testing remains essential. Furthermore, the timely initiation of disease-modifying therapies following acute-phase treatments demonstrates clear benefits in long-term follow-up.

PML also occurs as a serious adverse event for a subset of immunosuppressive therapies (e.g., natalizumab and rituximab) used to treat patients with immune disorders (e.g., multiple sclerosis and hematological malignancies). Interestingly, of the 4 genes with a PML risk variant, 2 (LY9 and STXBP2) cause or are linked to HLH. The aim of our review is two-fold: (1) raise awareness among researchers and clinicians (e.g., neurologists, oncologists, and rheumatologists) that patient genetics are a key risk factor for PML, and (2) further reinforce the rationale for screening at-risk patients for PML risk variants before prescribing a PML-linked drug.

Among approved DMT for MS and RA, teriflunomide and anti-CD20 therapies are the most suitable options for moderately or highly active MS with comorbid RA. Cladribine may also be considered, while TNFα inhibitors are contraindicated.

P1, N=10, Completed, Washington University School of Medicine | Active, not recruiting --> Completed

P=N/A, N=675, Completed, Biogen | Recruiting --> Completed

P1, N=10, Active, not recruiting, Washington University School of Medicine | Trial completion date: Dec 2025 --> Jun 2025 | Trial primary completion date: Dec 2025 --> Jun 2025

P=N/A, N=3526, Completed, Karolinska Institutet | Active, not recruiting --> Completed

P1, N=10, Active, not recruiting, Washington University School of Medicine | Recruiting --> Active, not recruiting